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Abstract 
The effect of glutathione co-therapy on the expression of gentamicin ototoxicity was tested in pigmented guinea pigs. The first 
group of animals was injected with gentamicin (100 mg/kg body weight/day) for two weeks followed by 10 weeks of rest. A 
second group received glutathione by gastric gavage immediately prior to each gentamicin injection. Two groups of controls were 
treated either with saline injections or glutathione gavage alone. Auditory brainstem responses, taken at 2-week intervals, 
revealed a progressive gentamicin-induced hearing loss teaching a 30 to 40 dB threshold shift at 2 kHz, approximately 60 dB at 8 
kHz and SO dB at 18 kHz. Glutathione co-therapy slowed the progression of hearing loss and significantly attenuated the final 
threshold shifts by 20 to 40 dB. Morphological evaluation confirmed hair cell loss after gentamicin treatment and protection by 
glutathione. Drug serum levels were assayed at 2 and 7 days of treatment. There were no differences between the gentamicin 
(mean = 183 pg/ml; range, 90 to 300) and the gentamicin/glutathione group (mean = 164 bg/ml; range, 80 to 320). 
Antimicrobial activity of gentamicin was tested against Staphylococcus aureuf and Pseudomonas aeruginosa. A 30-fold molar 
excess of glutathione did not influence the efficacy of gentamicin. These studies suggest that glutathione protects against 
ototoxicity by interfering with the cytotoxic mechanism. 
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1, Introduction 
After having been in therapeutic use for nearly five 
decades, aminoglycoside antibiotics are currently re- 
ceiving renewed attention. They were the first effica- 
cious drugs to combat tuberculosis, and opportunistic 
infections associated with AIDS have now brought a 
worldwide resurgence of this disease (Shafer et al., 
1991). Despite improvements in therapeutic regimen 
and development of new aminoglycosides, the nephro- 
and ototoxic potentials associated with this group of 
drugs have not yet been eliminated. The incidence of 
ototoxicity in patients - in the form of vestibuiar dis- 
turbances or auditory impairments - can be as high as 
18% for gentamicin and as low as 2% for netilmicin 
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(Fee, 1980; Matz, 1984). The damage frequently begins 
soon after the initiation of drug treatment, may con- 
tinue after cessation of therapy and is mostly perma- 
nent (Hawkins, 1976). 
Numerous attempts have been made to reduce the 
severity and frequency of the side-effects of aminogly- 
coside antibiotics, but these have been uniformly un- 
successful or unconvincing (reviewed by Federspil, 
19’79). A major handicap in designing rational preven- 
tive measures has been the lack of understanding of 
the precise mechanisms leading to hair cell destruction. 
However, recent studies have demonstrated the exis- 
tence of a cytotoxic gentamicin metabolite (‘gentatoxin’) 
providing a new theoretical basis for such attempts 
(Huang and Schacht, 1990; Crann et al., 1992). In fact, 
the cytotoxic actions of this metabolite against outer 
hair cells in vitro can be prevented by antioxidants and 
sul~yd~l compounds (Garetz and Schacht, 1992; 
Garetz et al., 1994). 
Glutathione (GSH) is a thiol-containing tripeptide 
found in virtually all mammalian cells. It plays a key 
role in a number of cellular processes including detoxi- 
fication of xenobiotics and protection against reactive 
oxygen species (Jakoby, 1978; Listowsky et al., 1988; 
Meister, 1991). Depletion of GSH potentiates drug-in- 
duced ototoxicity in vivo (Hoffman et al., 1988). and its 
presence protects outer hair cells in vitro against cyto- 
toxicity of the gentamicin metabolite (Garetz and 
Schacht, 1992; Garetz et al., 19941. These findings 
prompted the current study with the goal to determine 
if GSH could also protect the mammalian auditory 
system in vivo. 
2. Materials and Methods 
Experimental groups 
Pigmented adult guinea pigs (Murphy, Plainfield, 
NJ) weighing 250-400 g were used in this study. Con- 
trol groups (saline or GSH only) contained 5 animals 
each. Groups receiving gentamicin initially consisted of 
12-13 animals to allow for a sufficient number of 
surviving animals given the known morbidity of the 
drug at high doses. Each group was treated daily for 14 
days. Group 1 was injected with gentamicin sulfate 
(100 mg gentamicin base/kg body weight) intramuscu- 
larly. Group 2 was anesthetized with metaphane (drop 
inhalation method) and given 0.6 ml of 0.3 M GSH via 
gastric gavage. Thirty min later gentamicin was injected 
as above. Group 3 was anesthetized as above and then 
given 0.6 ml glutathione via gastric gavage. Group 4 
was injected intramuscularly with saline in a volume 
equivalent to that received by animals in group 1. Only 
animals who survived for the entire study period were 
included in the analysis. These were 5 of 5 animals in 
the saline group; 7 of 13 receiving gentamicin; 4 of 5 
receiving glutathione; and 6 of 12 on combined gen- 
tamicin/glutathione treatment. 
Evoked potentials 
Auditory thresholds were measured for each animal 
prior to the start of the study and then again at 2, 4, 8 
and 12 weeks after beginning of treatment. Animals 
were anesthetized with 40 mg/kg ketamine and 10 
mg/kg xylazine given by intramuscular injection. The 
recording electrodes consisted of needles inserted sub- 
cutaneously below the ipsilateral right pinna (reference 
electrode) and at the vertex (active electrode). The 
ground electrode was located in the right thigh because 
the more conventional use of the opposite ear was 
precluded by the positioning of the animals for the 
insertion of earphones. Placed at maximum distance 
from major vessels, this electrode did not cause any 
significant heart beat artifacts. Tone bursts of 3 ms 
duration with 1 ms rise and fall times were presented 
at 2, 8, and 18 kHz to the right ear through an inset 
speculum in the external auditory meatus. Stimuli were 
generated by a Fordham oscillator (model AG-298) 
and delivered via a Beyer DT-48 transducer. ABRs 
were recorded with a gain of 100,000 and filter settings 
of 100 Hz to 3 kHz. Average response tracings from 
512 sweeps were obtained at 5 dB intervals near 
threshold. Thresholds at each frequency were verified 
twice and defined as the intensity that produced ;I 
detectable change from a non-stimulus condition. Indi- 
vidual threshold shifts for each time point were calcu- 
lated by comparing intensity at threshold to the pre- 
treatment threshold for that animal at the same frc- 
quency. 
Serum gentamicin levels 
Two hundred ~1 of serum were obtained by toe nail 
clipping from animals treated with either gentamicin 
alone or with gentamicin and GSH on treatment days 2 
and 7. Samples were taken 30 min after injection. Cells 
were removed by centrifugation and plasma was stored 
at - 20°C until analysis. Immediately prior to assay the 
serum was thawed and diluted 1 : 100 with normal 
saline. Gentamicin levels were measured using a com- 
mercial fluorescence polarization immunoassay (Ab- 
bott Diagnostics, Abbott Park, IL). 
Cochlear morphology 
An apical opening was made in the extirpated right 
cochleae which were perfused with 0.1 M sodium ca- 
codylate, 2% paraformaldehyde, 2% glutaraldehyde 
and 2 mM calcium chloride. After 24 h of gentle 
rotation in the same fixative at 4°C cochleae were 
rinsed in phosphate buffer at 4°C for 2 days. Excess 
bone was removed and the cochleae were then decalci- 
fied in 3% EDTA at 4°C with gentle rotation for 2-3 
weeks. They were then dehydrated through a graded 
series of alcohol and embedded in EMbed 812 resin. 
Six-mm sections were cut in a para-modiolar plane and 
every third mid-modiolar section was mounted on a 
glass slide and stained with Richardson’s stain. Two 
animals from each of the four treatment condition 
were processed under double-blind conditions. Six 
comparable mid-modiolar sections from each animal 
were assessed using bright-field and differential inter- 
ference contrast optics on a Leitz photomicroscope. 
Antimicrobial activity 
Efficacy of gentamicin alone and in the presence of 
GSH was tested against Staphylococcus aureus (ATCC 
25923) and Pseudomonas aeruginosa (ATCC 27853) in 
a standard microbiological assay. Twenty ~1 of GSH 
were dispensed onto a 6 mm disk containing 10 Kg of 
gentamicin. The disks were placed on the surface of a 
150 mm culture plate containing Mueller-Hinton agar 
at a depth of 4 mm. The surface of the agar had 
previously been inoculated with a standardized concen- 
tration of either strain of bacteria. The inoculated 
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plates were incubated overnight at 35°C in room air. 
The diameter of the inhibition zones was measured to 
the nearest mm across each disk. These analyses were 
carried out by the Clinical Microbiology Laboratory, 
Department of Pathology, University of Michigan. 
3. Results 
Auditory brain stem response 
Auditory thresholds were comparable in all groups 
at the beginning of the study. Animals injected with 
saline or gavaged with GSH maintained essentially 
stable hearing at all of the measured frequencies (Fig. 
1). Animals receiving gentamicin showed the expected 
progressive hearing loss. Consistent with the estab- 
lished pattern of aminoglycoside ototoxicity (Hawkins, 
1976; Garetz and Schacht, 1994), the rate of threshold 
shift and its magnitude increased from low to high 
frequencies. Also, hearing loss continued after the 
2-week treatment and leveled off after 4 weeks at the 
high frequencies. Threshold shifts ranged from 30 dB 
at 2 kHz to about 80 dB at 18 kHz. Animals gavaged 
with GSH prior to gentamicin injection showed a slower 
progression of hearing loss at all frequencies and a 
significant reduction of the final threshold shift. Atten- 
uation of gentamicin toxicity ranged from about 20 dB 
at 2 kHz to 40 dB at 18 kHz. The brief anesthesia 
preceding GSH gavage apparently did not confound 
the treatment. Under a modified experimental design, 
glutathione administered without anesthesia also atten- 
uated aminoglycoside-induced hearing loss in animals 
maintained on a restricted diet (Lautermann and 
Schacht, 1994). 
It should be noted that the group of control animals 
tested at 12 weeks showed a jump of 30 to 40 dB in 
their thresholds. This phenomenon most likely repre- 
sented a testing artifact since the morphology in those 
animals (see below) was normal. Since there was no 
concomitant shift in the treated groups, this potential 
artifact produced thresholds in the control animals 
almost identical to those in the gentamicin/GSH group. 
Because of the uncertainty of the validity of the control 
thresholds and the resulting bias in interpretation, the 
12-week data were not included in the evaluation. 
Morphology 
Cochleae from two animals in each of the four 
treatment groups were examined histologically. Their 
morphology supported the electrophysiological findings 
that treatment with GSH exerted a protective influence 
on hair cells (Fig. 2). Sections from control animals 
treated with saline or GSH-gavage only showed normal 
morphology in all turns (Fig. 2a and b). Guinea pigs 
treated with gentamicin alone revealed almost com- 
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Fig. 1. Time course of threshold shifts at 2, 8 and 18 kHz. Four 
groups of animals were treated and ABR thresholds measured as 
described in ‘Methods’. Control groups not receiving gentamicin 
maintained stable thresholds while gentamicin induced progressive 
hearing loss. Differences between treatments were evaluated by 
ANOVA. There were no statistically significant differences between 
treatment with saline and GSH alone at any frequency. Threshold 
shifts induced by gentamicin were significantly different (P < 0.05) at 
8 and 12 kHz beginning at 4 weeks. GSH co-therapy significantly 
(P < 0.05) attenuated gentamicin-induced threshold shifts at 8 and 
18 kHz. N = 5 animals (saline); N = 4 (GSH only); N = 7 (gentami- 
tin only); N = 6 (gentamicin plus GSII). 
turns (Fig. 2c and d) consistent with the documented 
pattern of aminoglycoside-induced pathology (Hawkins, 
1976; Garetz and Schacht, 1994). There was also some 
loss of inner hair cells in the first turn. In contrast, less 
hair cell loss was apparent in animals treated with 
GSH gavage prior to administration of gentamicin (Fig. 
2e and f). 
Serum levels of gentamicin were unaffected by GSH 
treatment. On day 2 and 7, gentamicin concentrations 
averaged 183 pg/ml (range, 80 to 320). This was not 
statistically different from the mean of 164 pg/ml 
(range, 90 to 300) in the animals gavaged with GSH 
prior to their gentamicin injections (Fig. 3). 
Fig. 2. Histopathology of the organ of Corti. Animals were treated and histological sections obtained from two ammals in each group as 
described in ‘Methods’. Representative photomicrographs of mid-modiolar sections through the first turn of the cochlea of guinea pigs treated 
with saline (A), GSH oniy(B), gentamicin (Cl, D) and gentamicin plus GSH (E, F). Hair cell loss is seen with gentamicin (C, D) administration, 
but less so if there was pre-treatment with GSH before gentamicin (E, F). Saline (A) and GSH (B) controls showed no effects on cochiear 
structures. 
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Table 1 
Glutathione does not affect antimicrobial activity of gentamicin 
Condition Inhibition zones 
S uureus P aeruginosa 
20 nmol (10 ,ugl gentamicin 
Gentamicin plus 20 nmol GSH 
Gentamicin plus 600 nmol GSH 
23+ 1 19&l 
22 19 
22 I9 
Inhibition zones were measured in a microbiological assay against 
Staphyi~~ei~~~l~.s mreus and ~~ez~~umonus aeruginosu as described in 
‘Methods‘. 
Antirnicrobiai efficacy 
Gentamicin efficacy against Streptococcus aureus and 
Pseudomonas aeruginosa was tested in a standard an- 
timicrobial assay. The inhibition zones produced by 10 
kg gentamicin remained unaffected by GSH up to a 
30-fold molar excess, the highest concentration tested 
(Table 1). 
4, Discussion 
Enteral administration of glutathione prior to gen- 
tamicin treatment clearly reduced the extent of gen- 
tamicin-induced hearing loss in guinea pigs at high and 
low frequencies as compared to animals receiving gen- 
tamicin alone. The effect was already evident at the 
end of the two-week regimen, the earliest time at 
which responses were measured. In agreement with the 
established pattern of gentamicin toxicity, the hearing 
loss progressed after cessation of treatment but the 




L? 6- ” 
; g 
z 5- $3 







z’ 2- z 
1 
l- 
electrophysiological observations were confirmed by the 
histology: gentamicin produced the expected loss of 
hair cells while GSH co-therapy attenuated hair cell 
death. 
Depletion of GSH, either by starvation (Prazma et 
al., 1983; Hoffman et al., 1987) or by enzymatic inhibi- 
tion (Hoffman et al., 1988) has been shown to potenti- 
ate the ototoxicity associated with aminoglycosides ad- 
ministered either alone or in conjunction with loop 
diuretics. Our data is the first indication that the 
converse effect also occurs. Importantly, the afforded 
protection is not mediated by an effect on drug serum 
levels which otherwise would compromise the thera- 
peutic efficacy of the treatment. The best explanation, 
in view of results recently obtained by our laboratory 
(Crann et al., 1992; Garetz and Schacht, 1992; Garetz 
et al., 1994) is a direct interference by GSH with the 
cytotoxic mechanism of gentamicin. In vitro toxicity 
assays have demonstrated that gentamicin will not de- 
stroy outer hair cetls in short-term culture. However, 
after an enzymatic reaction the resulting gentamicin 
metabolitc is acutely cytotoxic. This metabolic step, 
apparently necessary for the expression of gentamicin 
toxicity, can be inhibited in vitro by radical scavengers 
and sulfhydryl compounds including GSH (Garetz et 
al., 1994). As demonstrated here, the toxic effect of 
gentamicin in vivo can likewise be attenuated by GSH. 
Sulfhydryl compounds as ameliorating agents for 
ototoxic drugs have been tested before with varying 
success. One example of the difficulties encountered in 
establishing the efficacy of antidotes was the experi- 
ence with the suI~yd~~ agent 2,3-mercaptopropanol. 
Claims of attenuation of aminoglycoside ototoxicity by 
Serum Gentamicin Levels 
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Fig. 3. Serum levels of gentamicin. Serum levels of ~entamic~n were obtained after 2 and 7 days of treatment as described in ‘Methods’. Values in 
animals receiving GSH co-therapy did not differ statistically from values in animals receiving gentamicin alone. 
this compound had been made in the 1950s and 1960s 
based on animal experimentation and clinical trials. 
Subsequently, these reports were disputed and 2,3- 
mercaptopropanol was shown to be toxic in itself 
(Federspil, 1979). GSH was also tested and found 
ineffective against kanamycin (Darrouzet, 1967). It 
should be considered, however, that GSH homeostasis 
in vivo is subject to many factors including nutritional 
status, stress, and health of the animal. Successful 
amelioration of toxic side effects may therefore depend 
on the physiological state of the animal. An animal 
already challenged by undernutrition or pathogenic 
infection should be more susceptible to ototoxic insults 
than normal animals because of weakened intrinsic 
protective mechanisms. Thus, such animals may re- 
spond more favorably to co-therapy. This variable might 
explain the scattered claims of success with vitamins, 
amino acids or similar supplements. Interestingly, after 
the completion of this study it became known that the 
colony from which the animals were derived suffered 
from a viral infection. Although impossible to deter- 
mine in retrospect, these animals may have provided a 
test model already challenged by infections. This as- 
pect of restoring protective homeostatic mechanisms by 
GSH warrants further exploration. 
Co-therapy introduces a second drug and therefore 
possible added complications. However, sulfhydryl 
compounds are well-established drugs in antioxidant 
therapy (Rice-Evans and Diplock, 1993). In particular, 
GSH can be manipulated by diet or intravenous admin- 
istration (Hagen et al., 1990; Wendel and Jaeschke, 
1981) without apparent side effects of elevated serum 
levels. On the contrary, GSH administration has been 
investigated in humans to prevent adverse side effects 
of a variety of medications (Cavalletti at al., 1986; 
Oriana et al., 1987). 
Finally, an effective intervention against gentamicin 
ototoxicity must not compromise the therapeutic effi- 
cacy of the drug. GSH appears to fulfill this condition. 
Firstly, it does not alter serum levels of gentamicin. 
Secondly, it does not affect the bactericidal efficacy of 
the antibiotic as determined against two representative 
pathogens. Thus, the lack of deleterious actions and 
the ease of administration suggest GSH as an ideal 
agent to reduce the ototoxicity associated with amino- 
glycoside administration. 
Acknowledgments 
We wish thank Dr. Sanford Bledsoe for help with 
the electrophysiological recordings. We also like to 
acknowledge William Hubbard and the Clinical Micro- 
biology Laboratory at the University of Michigan for 
the determination of the antimicrobial efficacy of gen- 
tamicin. This work was supported by grant DC-00124 
and training grant DC-00024 from the National lnsti- 
tutes of Health. 
References 
Cavalletti, E., Tofanetti, 0. and Zunino, F. (1986) Comparison of 
reduced glutathione with 2-mercaptoethane sulfonate to prevent 
cyclophosphamide-induced urotoxicity. Cancer Lett. 32, I-6. 
Crann, S.A., Huang, M.Y., McLaren, J.D. and Schacht, J. (1992) 
Formation of a toxic metabolite from gentamicin by a hepatic 
cytosolic fraction. Biochem. Pharmacol. 43, 1835-1839. 
Darrouzet, J. (1967) Essais de protection de l’organe de Corti contre 
I’ototoxicit8 des antibiotiques. Rev. Laryngol. 3-4, 187-203. 
Federspil, P. (1979) Antibiotikaschiden des Ohres. Barth, Leipzig, 
pp. 86-89. 
Fee, W.E. jr. (1980) Aminoglycoside ototoxicity in the human Laryn- 
goscope Suppl 24, 1-19. 
Garetz, S. and Schacht, J. (1992) Sulfhydryl compounds reduce 
gentamicin-induced outer hair cell damage in vitro. Abs. Assoc. 
Res. Otolaryngol. 15, 110. 
Garetz, S., Rhee, D.J. and Schacht, J. (1993) Attenuation of gentam- 
icin ototoxicity by glutathione. Abs. Assoc. Res. Otolaryngol. 16, 
141. 
Garetz, S.L., Rhee, D.J. and Schacht, J. (1994) Sulfhydryl com- 
pounds and antioxidants inhibit cytotoxicity to outer hair cells of 
a gentamicin metabolite in vitro. Hear. Res., in press. 
Garetz, S. and Schacht, J. (1994) Ototoxicity: Of mice and men. In: 
Handbook of Auditory Research (Fay, R.R. and Popper, A.N., 
Eds.), Vol. VI: Clinical Aspects of Hearing (VanDeWater, T.R. 
Ed.), Springer-Verlag, New York, in press. 
Hagen, T.M., Wierzbicka, G.T., Bowman, B.B. AW, T.Y. and Jones. 
D.P. (1990) Bioavailability of dietary glutathione: effect on plasma 
concentration. Am. J. Physiol. 259, G524-G.529. 
Hawkins, J.E. jr. (1976) Drug ototoxicity. In: Handbook of Sensory 
Physiology (W.D. Keidel and W.D. Neff, Eds.), Springer, New 
York, Vol. 5, pp. 707-748. 
Hoffman, D.W., Whitworth, C.A., Jones, K.L. and Rybak, L.P. 
(1987) Nutritional status, glutathione levels, and ototoxicity of 
loop diuretics and aminoglycoside antibiotics. Hear. Res. 31. 
217-222. 
Hoffman, D.W., Whitworth, CA., Jones-King, K.L. and Rybak, L.P. 
(1988) Potentiation of ototoxicity by glutathione depletion. Ann. 
Otol. Rhinol. Laryngol. 97, 36-41. 
Huang, M.Y. and Schacht, J. (1990) Formation of a cytotoxic 
metabolite from gentamicin by liver. Biochem. Pharmacol. 40, 
Rll-R14. 
Jakoby. W.B. (1978) The glutathione S-transferases: a group of 
multi-functional detoxification proteins. Adv. Enzymol. 46, 383- 
414. 
Lautermann, J. and Schacht, J. Effects of glutathione and antioxi- 
dants on gentamicin ototoxicity in different nutritional states. 
Abstr. Assoc. Res. Otolaryngol. 17, 64, 1994. 
Listowsky, I., Abramovitz, M., Homma, H. and Niitu, Y. (1988) 
Intracellular binding and transport of hormones and xenobiotics 
by glutathione S-transferases. Drug Met. Rev. 19, 305-318. 
Matz, G.J. (1986) Amminoglycoside ototoxicity. Am. J. Otolaryngol. 
7, 117-119. 
Meister, A. (1991) Glutathione deficiency produced by inhibition of 
its synthesis, and its reversal; application in research and therapy. 
Pharmac. Ther. 55, 155-194. 
Oriana, S., Bohm, S., Spatti, G., Zunino, F. and Di Re, F. (1987) A 
preliminary clinical experience with reduced glutathione as pro- 
tector against cisplatin-toxicity. Tumori 73, 337-340. 
XL. Garetz et al. /Hearing Research 77 (19941 81-87 x7 
Prazma, J., Garrison, H.G., Williford, S.K., Ferguson, S.D., Fisher, 
J., Drake, A. and Klingler, L.E (1983) Alteration of aminoglyco- 
side antibiotic ototoxicity: effect of semistarvation. Ann. Gtol. 
Rhinol. Laryngol. 92, 178-182. 
Rice-Evans, C.A. and Diplock, A.T. (1993) Current status of antioxi- 
dant therapy. Free Radical Biol Med 15, 77-96. 
Shafer. R.W.. Chirgwin. K.D., Glatt, A.E., Dahdouh. M.A., Landes- 
man, S.H. and Suster. B. (1991) HIV prevalence. immunosup- 
pression. and drug resistance in patients with tuberculosis in an 
area endemic for AIDS. AIDS 5, 399-405. 
Wendel, A. and Cikryt. P. (19HO) The level and half-life of glu- 
tathione in human plasma. FEBS Lett. 120, 209-211. 
Wendel, A. and Jaeschke, H. (1981) Drug-induced lipid peroxidation 
in mice. III. Glutathione content of liver. kidney, and spleen after 
intravenous administration of free and liposomally entrapped 
glutathione. Biochem. Pharmacol. 31. 36077361 I. 
